Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Instem upbeat on outlook as it updates on 2016 progress

The company’s investment in a product that complies with the US Food & Drug Administration’s Standard for Exchange of Nonclinical Data, or SEND protocol, appears well-judged.
Instem upbeat on outlook as it updates on 2016 progress
The company's software is used to collate data from clinical trials

Instem Plc (LON:INS), developer and vendor of software used to log clinical trials, said it has started the new year in good heart after providing some granularity on its performance in 2016.

Already-flagged-up contract delays and the “disappointing performance” of Instem Clinical offset the strong performance of the bulk of the business.

The company’s investment in a product that complies with the US Food & Drug Administration’s Standard for Exchange of Nonclinical Data, or SEND protocol, appears well-judged.

In all it won 30 SEND-related contracts for its software – which makes it a leader in this field.

For the 12 months to December 31, revenues increased 11% to £18.1mln, Instem said, giving EBITDA of £1.2mln. Cash at the year-end was £4.4mln.

"Although the slowdown in the early phase clinical market and contract delays were disappointing, other parts of the business continued to perform well and we made significant progress during the year,” said chief executive Phil Reason. 

“Importantly, the overall market dynamics for our products and services remains positive and we therefore look forward to the next financial year with increasing optimism."

View full INS profile View Profile

Instem Plc Timeline

Related Articles

Trading screen
June 13 2018
Following a root and branch overhaul, the company is setting its sights firmly on a SaaS business model as it reconnects with its technology pedigree
nasstar
March 22 2018
Nasstar has been integrating all the businesses it has acquired since 2014 to operate as one organisation.
Cloudbuy's online purchasing portal
April 18 2018
"We remain convinced that we have a unique product and a great partner in NHS Shared Business Services to maximise the roll-out of PHB's and Integrated Commissioning across Health and Social Care," the company said.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use